Palliative Stenting With or Without Radiotherapy for Inoperable Esophageal Carcinoma: A Randomized Trial

Javed, Amit; Pal, Sujoy; Dash, Nihar Ranjan; Ahuja, Vineet; Mohanti, Bidhu Kalyan; Vishnubhatla, Sreenivas; Sahni, Peush; Tk, Chattopadhyay

doi:10.1007/s12029-010-9206-4

Cited by 66 publications

(83 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 It is diagnosed in about 400,000 patients each year worldwide, and its incidence is increasing. 2 Due to the lack of widespread screening methods, its insidious symptomatology, a late clinical presentation, and rapid progression, diagnosis is usually made at advanced stages.…”

Section: Introductionmentioning

confidence: 99%

“…2 Due to the lack of widespread screening methods, its insidious symptomatology, a late clinical presentation, and rapid progression, diagnosis is usually made at advanced stages. 1,3 Therefore the 5-year survival rate of patients with esophageal cancer is less than 20%. Most patients already present with locally advanced, unresectable or metastatic disease and only suitable for palliative therapy.…”

Section: Introductionmentioning

confidence: 99%

“…Most patients already present with locally advanced, unresectable or metastatic disease and only suitable for palliative therapy. 3 The predominant symptom of advanced esophageal cancer is dysphagia with 80-90% of all 1 It is one of the most distressing and debilitating symptoms in patients with cancer-related esophageal obstruction. Dysphagia leads to nutritional compromise, pain, and deterioration of quality of life.…”

Section: Introductionmentioning

confidence: 99%

“…3 As the quality of life, and to some extent the quantity of life remaining to these patients depends to a large degree on their ability to swallow, the relief of dysphagia is therefore a priority for any palliative treatment of patients suffering from esophageal cancer. 1,3 Several treatment modalities are used for the palliative care of dysphagia in patients with inoperable esophageal cancer, including radiotherapy (endoluminal and external-beam), endoscopic ablation (for example, by laser, cryotherapy, photodynamic therapy), endoluminal plastic and metallic stents, and resection or bypass surgery. Of those approaches, endoluminal stenting and radiation therapy are the ones most commonly used.…”

Section: Introductionmentioning

confidence: 99%

“…Radiotherapy, in turn, provides lasting dysphagia relief by retarding tumor growth and, possibly, improves survival. 1 This paper was aimed to evaluate the comparison of palliative treatment using esophageal stenting alone or in combination with radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Palliative Stenting With or Without Radiotherapy for Inoperable Esophageal Carcinoma

Utami

Fauzi

2015

InaJGHE

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Palliative Stenting With or Without Radiotherapy for Inoperable Esophageal Carcinoma

Utami

Fauzi

2015

InaJGHE

View full text Add to dashboard Cite

show abstract

Use and Reporting of Patient-Reported Outcomes in Trials of Palliative Radiotherapy

et al. 2022

View full text Add to dashboard Cite

ImportanceApproximately 50% of all patients with cancer have an indication for radiotherapy, and approximately 50% of radiotherapy is delivered with palliative intent, with the aim of alleviating symptoms. Symptoms are best assessed by patient-reported outcomes (PROs), yet their reliable interpretation requires adequate reporting in publications.ObjectiveTo investigate the use and reporting of PROs in clinical trials of palliative radiotherapy.Evidence ReviewThis preregistered systematic review searched PubMed/Medline, EMBASE, and the Cochrane Center Register of Controlled Trials for clinical trials of palliative radiotherapy published from 1990 to 2020. Key eligibility criteria were palliative setting, palliative radiotherapy as treatment modality, and clinical trial design (per National Institutes of Health definition). Two authors independently assessed eligibility. Trial characteristics were extracted and standard of PRO reporting was assessed in adherence to the Consolidated Standards of Reporting Trials (CONSORT) PRO extension. The association of the year of publication with the use of PROs was assessed by logistic regression. Factors associated with higher CONSORT-PRO adherence were analyzed by multiple regression. This study is reported following the PRISMA guidelines.FindingsAmong 7377 records screened, 225 published clinical trials representing 24 281 patients were eligible. Of these, 45 trials (20%) used a PRO as a primary end point and 71 trials (31%) used a PRO as a secondary end point. The most prevalent PRO measures were the Numeric Rating Scale/Visual Analogue Scale (38 trials), European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire C30 (32 trials), and trial-specific unvalidated measures (25 trials). A more recent year of publication was significantly associated with a higher chance of PROs as a secondary end point (odds ratio [OR], 1.04 [95% CI, 1.00-1.07]; P = .03) but not as primary end point. Adherence to CONSORT-PRO was poor or moderate for most items. Mean (SD) adherence to the extension adherence score was 46.2% (19.6%) for trials with PROs as primary end point and 31.8% (19.8%) for trials with PROs as a secondary end point. PROs as a primary end point (regression coefficient, 9.755 [95% CI, 2.270-17.240]; P = .01), brachytherapy as radiotherapy modality (regression coefficient, 16.795 [95% CI, 5.840-27.751]; P = .003), and larger sample size (regression coefficient, 0.028 [95% CI, 0.006-0.049]; P = .01) were significantly associated with better PRO reporting per extension adherence score.Conclusions and RelevanceIn this systematic review of palliative radiotherapy trials, the use and reporting of PROs had room for improvement for future trials, preferably with PROs as a primary end point.

show abstract

Interventions for dysphagia in oesophageal cancer

Dai

Xie

et al. 2014

Cochrane Database of Systematic Reviews

113

102

View full text Add to dashboard Cite

show abstract

Palliative Stenting With or Without Radiotherapy for Inoperable Esophageal Carcinoma: A Randomized Trial

Abstract: Post-stenting EBRT effectively prolongs duration of dysphagia relief and improves overall survival in inoperable esophageal cancer.

Cited by 66 publications

References 21 publications

Palliative Stenting With or Without Radiotherapy for Inoperable Esophageal Carcinoma

Palliative Stenting With or Without Radiotherapy for Inoperable Esophageal Carcinoma

Use and Reporting of Patient-Reported Outcomes in Trials of Palliative Radiotherapy

Interventions for dysphagia in oesophageal cancer

Contact Info

Product

Resources

About